Viking Therapeutics (VKTX) Is Up 7.0% After Completing Enrollment In Key VANQUISH-2 Obesity Trial

Simply Wall St.04-06

Viking Therapeutics recently announced it has completed patient enrollment in VANQUISH-2, its Phase 3, 78-week trial of once-weekly subcutaneous VK2735 in about 1,000 adults with type 2 diabetes who ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625281456?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-06 03:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625281456","market":"us","top_or_hot":-1,"title":"Viking Therapeutics (VKTX) Is Up 7.0% After Completing Enrollment In Key VANQUISH-2 Obesity Trial","media":"Simply Wall St.","content":"<div>\n<p>Viking Therapeutics recently announced it has completed patient enrollment in VANQUISH-2, its Phase 3, 78-week trial of once-weekly subcutaneous VK2735 in about 1,000 adults with type 2 diabetes who ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-is-up-70-after-completing-enrollmen\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viking Therapeutics (VKTX) Is Up 7.0% After Completing Enrollment In Key VANQUISH-2 Obesity Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViking Therapeutics (VKTX) Is Up 7.0% After Completing Enrollment In Key VANQUISH-2 Obesity Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-06 03:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-is-up-70-after-completing-enrollmen><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Viking Therapeutics recently announced it has completed patient enrollment in VANQUISH-2, its Phase 3, 78-week trial of once-weekly subcutaneous VK2735 in about 1,000 adults with type 2 diabetes who ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-is-up-70-after-completing-enrollmen\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-is-up-70-after-completing-enrollmen","article_id":"2625281456","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-is-up-70-after-completing-enrollmen","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2625281456","pubTimestamp":1775416862,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Viking Therapeutics recently announced it has completed patient enrollment in VANQUISH-2, its Phase 3, 78-week trial of once-weekly subcutaneous VK2735 in about 1,000 adults with type 2 diabetes who are obese or overweight.\nThis milestone moves Viking’s lead dual GLP-1/GIP agonist closer to pivotal data in obesity and diabetes, building directly on prior Phase 2 VENTURE results showing clinically meaningful weight loss and an encouraging safety profile.\nWe’ll now examine how completing...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4599":"减肥药","VKTX":"Viking Therapeutics, Inc.","BK4588":"碎股"},"translate_title":"Viking Therapeutics(VKTX)在完成关键VANQUISH-2肥胖试验的入组后股价上涨7.0%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":1.5},"content_text":"Viking Therapeutics recently announced it has completed patient enrollment in VANQUISH-2, its Phase 3, 78-week trial of once-weekly subcutaneous VK2735 in about 1,000 adults with type 2 diabetes who are obese or overweight. This milestone moves Viking’s lead dual GLP-1/GIP agonist closer to pivotal data in obesity and diabetes, building directly on prior Phase 2 VENTURE results showing clinically meaningful weight loss and an encouraging safety profile. We’ll now examine how completing enrollment in the VANQUISH-2 Phase 3 trial could influence Viking Therapeutics’ broader obesity-focused investment narrative. Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.AdvertisementViking Therapeutics Investment Narrative RecapTo own Viking Therapeutics, you have to believe VK2735 can successfully transition from a late stage obesity and diabetes asset into a commercial product before cash pressures bite. Completing VANQUISH-2 enrollment is a clear operational step toward pivotal data, but it does not remove the near term risk that any setback in the VANQUISH program or the oral VK2735 path could extend losses and increase the likelihood of shareholder dilution. The VANQUISH-2 milestone sits alongside Viking’s earlier completion of enrollment in VANQUISH-1, reinforcing that the company’s largest current catalyst is a pair of Phase 3 trials aimed at obesity and obesity with type 2 diabetes. Together with the maintenance dosing study expected to read out in the third quarter of 2026, these programs frame both the upside case around VK2735’s potential and the execution risk tied to Viking’s rapid ramp in R&D spending. Yet investors should also be aware that if VANQUISH data disappoints, Viking’s heavy spending and reliance on cash reserves could... Read the full narrative on Viking Therapeutics (it's free!)Viking Therapeutics’ narrative projects $118.5 million in revenue and $12.9 million in earnings by 2029. This requires revenue to grow from zero and a $372.5 million earnings increase from -$359.6 million today.Uncover how Viking Therapeutics' forecasts yield a $92.72 fair value, a 166% upside to its current price.Exploring Other PerspectivesVKTX 1-Year Stock Price Chart Completion of VANQUISH-2 sharpens this debate: bullish analysts were already modeling about US$497.5 million of revenue and US$62.2 million of earnings by 2029, so if you are weighing that optimistic path against the risk that longer, more complex trials keep costs elevated for years, it is worth recognizing how far apart reasonable views of Viking’s future can be.Explore 20 other fair value estimates on Viking Therapeutics - why the stock might be worth 21% less than the current price!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Viking Therapeutics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.Our free Viking Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viking Therapeutics' overall financial health at a glance.Ready For A Different Approach?Our daily scans reveal stocks with breakout potential. Don't miss this chance:Uncover the next big thing with 33 elite penny stocks that balance risk and reward.Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625281456","isCrawlerRequest":true}